Equities analysts predict that ADMA Biologics Inc (NASDAQ:ADMA) will announce ($0.42) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for ADMA Biologics’ earnings, with estimates ranging from ($0.54) to ($0.29). ADMA Biologics posted earnings of ($0.50) per share in the same quarter last year, which suggests a positive year over year growth rate of 16%. The company is scheduled to issue its next quarterly earnings results on Friday, August 11th.

On average, analysts expect that ADMA Biologics will report full year earnings of ($1.64) per share for the current year, with EPS estimates ranging from ($2.16) to ($1.29). For the next financial year, analysts anticipate that the business will post earnings of ($1.47) per share, with EPS estimates ranging from ($2.06) to ($1.04). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Friday, May 12th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.23. The firm had revenue of $2.63 million for the quarter, compared to analyst estimates of $3.35 million.

Several equities research analysts have weighed in on ADMA shares. Maxim Group set a $13.00 price objective on shares of ADMA Biologics and gave the company a “buy” rating in a research report on Wednesday, June 7th. ValuEngine lowered shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/12/zacks-brokerages-anticipate-adma-biologics-inc-nasdaqadma-will-announce-earnings-of-0-42-per-share.html.

Shares of ADMA Biologics (NASDAQ:ADMA) opened at 2.94 on Friday. The company has a 50-day moving average of $3.47 and a 200-day moving average of $4.19. ADMA Biologics has a 12 month low of $2.76 and a 12 month high of $7.70. The firm’s market cap is $37.88 million.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.